Compugen Reports Second Quarter 2026 Results

Compugen Ltd. (NASDAQ: CGEN) reported Q2 2026 results and a corporate update. The MAIA-ovarian trial of COM701 is progressing, with median progression-free survival interim data expected in Q1 2027. Partner AstraZeneca presented GEMINI-Hepatobiliary overall survival data for rilvegostomig (median 16.8 months). Cash was about $125.3M, funding operations into 2029. Q2 revenue was ~$2.6M vs ~$1.3M in 2025; net loss ~$7.0M.

Original reporting
Published Aug 3, 2026, 11:45 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 3, 2026, 12:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$CGEN
Bullish
medium confidence
Mentioned
$CGEN
Relevance
7/10
AlphAI data visualization · based on prnewswire.com
Decision brief

The 30-second read

$CGENBullishMed
01

Why it matters

This release combines (1) Q2 2026 financial updates, (2) a reiterated clinical catalyst timeline for COM701 in platinum-sensitive ovarian cancer, and (3) partner program progress and a new overall survival readout for AstraZeneca’s rilvegostomig in biliary tract cancer.

02

Market read

Traders can use the reiterated COM701 interim-analysis timing (Q1 2027) and the stated cash runway into 2029 to frame biotech risk, while the new partner OS readout for rilvegostomig adds sentiment support for the broader checkpoint-pathway theme.

03

What to watch

Cash runway into 2029 is supportive, but the article does not quantify trial enrollment progress, event counts, or probability of success for COM701, which are key drivers of valuation for pre-registration-stage assets.

Relevance 7/10Novelty 6/10Timing: today’s Aug 3 pre-market/market open context ahead of the company’s 8:30 AM ET call

Background

Compugen is a clinical-stage cancer immunotherapy company with an AI/ML discovery platform (Unigen) and partnered programs including AstraZeneca’s rilvegostomig and Gilead’s GS-0321.

Company-level read

Ticker impact

$CGENBullishMedium confidence
Context

Compugen reported Q2 2026 results and said its MAIA-ovarian COM701 interim analysis with median PFS is expected by Q1 2027.

Expected impact

Moderate positive bias, with volatility likely into the next clinical milestone and any follow-on partner updates.

Evidence & confidence

The article provides fresh company-specific disclosures: Q2 financials, cash runway guidance, and a reiterated timing for the COM701 interim analysis. However, it does not include a new efficacy datapoint or regulatory decision that would typically drive a large immediate repricing.

Market effects

Reinforces investor attention on checkpoint-pathway innovation beyond PD-1/TIGIT (PVRIG) and on platform trial readouts as catalysts for oncology immunotherapy developers.

Limited direct regional spillover; primarily impacts US-listed biotech sentiment.

Partnered late-stage oncology programs (AstraZeneca) and IL-18 pathway interest (Gilead-linked GS-0321) may marginally influence global biotech risk sentiment.

Counterpoint

The reiterated Q1 2027 interim-analysis timing is not a new clinical result, so the market may already be pricing the catalyst; near-term reaction could fade if investors want hard efficacy updates sooner.

Key entities

  • Compugen Ltd.

    Subject of the earnings and corporate update, including COM701 MAIA-ovarian interim-analysis timing and Q2 2026 financial highlights.

  • COM701

    Compugen’s anti-PVRIG antibody in the MAIA-ovarian adaptive platform trial; interim median PFS expected by Q1 2027.

  • AstraZeneca

    Partner presenting rilvegostomig data at ASCO 2026 and initiating an additional Phase 3 trial.

  • rilvegostomig

    PD-1/TIGIT bispecific antibody; ASCO 2026 first overall survival readout reported with median OS 16.8 months.

  • Gilead

    Partner for GS-0321, with the Phase 1 dose-escalation trial progressing as planned.

Related articles

$CGENMed

Compugen stock maintained at Buy by H.C. Wainwright, $4 target

H.C. Wainwright maintained a Buy rating and $4.00 target on Compugen (CGEN) after Q3 results. The stock trades at $2.09, up 9% in a week and 37% YTD. Compugen completed enrollment for its MAIA-ovarian study, with results expected by Q1 2027. Q3 revenue was $3.8M, up from $1.9M YoY but below estimates. The company expects sufficient cash to support operations through 2029.

$CGENMed

What Compugen (CGEN) Said on Its Q3 Earnings Call

Compugen (CGEN) reported Q3 revenue of $3.8M, up from $1.9M YoY. The company discussed milestones for its partnered programs with AstraZeneca and Gilead, including potential payments and royalties. Compugen also introduced UnigenX, an expansion of its AI-powered discovery engine. The net loss narrowed to $5.8M, or $0.06 per share, with $117.5M in cash equivalents.

$DISMedAI 8/10

Disney’s Experiences Segment Hit Record Quarterly Revenue of $10.1 Billion as Cruise Days Surged. Can the Momentum Last?

Disney (DIS) reported Q4 2026 revenue of $25.95B, up 16% YoY, with its Experiences segment hitting a record $10.1B. All units grew, with Experiences leading in operating income at $2.25B. Adjusted net income rose 56% to $3.35B, beating estimates. The company plans to invest $60B in Experiences over a decade, focusing on parks and cruises.

$GLADMed

Gladstone Capital (GLAD) Q4 2026 Earnings Call Transcript

Gladstone Capital (GLAD) reported Q4 2026 earnings with net interest margin at 8.2%. Fee income was below average, but incentive fee credit covered 100% of regular distributions. Net asset value declined to $20.77 per share due to unrealized depreciation and a supplemental distribution. Total investment income rose 11.7% for the year, covering distributions at 104.5%. The company discussed its investment strategy and credit management, highlighting its focus on the lower middle market.

$NVDAHighAI 9/10

Nvidia's $130 Billion Forecast Sparks Fresh AI Stock Rally

Nvidia's shares rose 2% premarket after reporting Q3 sales of $115.84B, up 4x, and raising its fiscal 2028 sales growth target to ~75%. The company also guided to a gross margin of 71-72% for the current quarter. AI-related stocks also gained. Nvidia's board is searching for a permanent CEO after rejecting Jensen Huang's return. The company excluded future China shipments from its projections.